Search results
-
Dr Julian Sale
... to monitor the molecular choreography of proteins and DNA at sites of stalled replication. ...
-
Professor Duncan Jodrell
I endeavour to integrate and optimise the pre-clinical development and science-led clinical application of novel therapies and novel therapeutic combinations, including first into man (phase I) and associated studies. My research goal is to identify...
-
Dr K Gatley
... 170 patients being recruited from UK participating sites. ...
-
Professor Ming-Qing Du
... B or T lymphocytes and occur at both nodal and extranodal sites. The accurate diagnosis of various lymphoma subtypes is critical in ...
-
Dr Richard Baird
Early phase clinical trials, including expertise in: ...
-
Miss Rachel Matthews
... to extract a small number of cells from multiple tumour sites; this sampling method provides a better capture of the cell populations ...
-
Dr Daniel Hodson
... cells or memory B cells, whereas less competitive B cells default to apoptosis. Rapidly changing, but tightly controlled, programmes of ...
-
Professor Jean Abraham
-
-
Dr Oscar M Rueda
Development of statistical methods and models for the analysis and integration of breast cancer high-throughput data: detection of alterations in DNA copy number and their influence in mRNA expression and survival, in order to obtain predictive markers....
-
Dr Robin Hesketh
I am based in the Biochemistry Department and work on several cancer related projects, primarily in collaboration with Jim Metcalfe, Kevin Brindle and Doug Easton. These fall into four areas (1) Development of anti-angiogenic gene therapy, (2) Studies...
-
Professor Antonis Antoniou
... evaluation of risk prediction models for familial breast, ovarian, prostate and other cancers with a familial component; - the ...
-
Dr Alison Dunning
... closely with the international consortia for breast, ovarian, endometrial and prostate cancer association studies: BCAC ...
-
Dr Anna Piskorz
... focus on translational research in high grade serous ovarian cancer (HGSOC). I work on identification of genomic biomarkers that ...
-
Dr Bristi Basu
I co-lead the Cambridge Experimental Cancer Medicine Centre with Prof Duncan Jodrell and the CRUK Cambridge Centre Pancreatic Cancer Programme with Dr Giulia Biffi. Other roles include Capacity Building leadership team within the Cambridge NIHR...
-
Dr Daniel Barnes
... These individuals are at increased risk of breast cancer and ovarian cancer in women, and breast cancer and prostate cancer in men. I am ...
-
Professor Steve Charnock-Jones
... underlying the progression from endometriosis to clear cell ovarian cancer. Endometriosis is a relatively common condition affecting ... of these cases there is an increased incidence of clear cell ovarian cancer. Recent work has shown that mutations in Arid1a gene are ...
-
Professor Evis Sala
Now based in Rome, my research in Cambridge focused on integrated diagnostics, through the clinical development and validation of functional imaging biomarkers to rapidly evaluate treatment response using physiologic and metabolic tumour habitat imaging...
-
Dr Geoff Macintyre
... associated with treatment resistance in high-grade serous ovarian cancer (HGSOC). These methods are developed using whole-genome ...
-
Dr Honglin Song
I am working on genetic susceptibility to the risk of ovarian cancer and clinical outcome after a diagnosis of ovarian cancer. I have led the work of the group in common/rare gene variation ...
-
Professor James Brenton
... clinical trials with sequential collection and profiling of ovarian cancer tissues before and during therapy. Array-based expression ...
-
Professor Anthony Davenport
... pathophysiology (recently implicated in tumourigenesis of cancers) and discovering role in man of novel ?orphan? GPCRS, originally ...
-
Dr Richard Benson
... and chemoradiotherapy in head and neck and urological cancers, develpoing technical radiotherapy and evaluating treatment related ...
-
Dr Mariann Bienz
... of the Wnt pathway has been linked to a wide range of cancers. Notably, the majority of colorectal cancers are due to inactivating mutations of the APC tumour suppressor, or to ...
-
Dr Chiwen Chang
... Class I antigen during immune response. 2. Immunotherapy for cancers and autoimmune diseases. ...
-
Professor Carlos Caldas
... CANCER FUNCTIONAL GENOMICS The molecular taxonomy of breast cancers has revealed a complexity that suggests that different cancers have different cells of origin. The identification and characterisation ...
-
Dr Christopher Jones
... response and post-radiation monitoring of oesophageal cancers, with a particular focus on oesophageal adenocarcinoma. I am also ...
-
Dr Pippa Corrie
... based on improving outcomes for patients with chemoresistant cancers. I am chief investigator of the national adjuvant melanoma phase 3 ...
-
Dr Danish Mazhar
... 2007. His clinical and research interests are in Urological Cancers. He is the Principal Investigator of numerous clinical trials in Prostate, Bladder and Testis Cancers. He is a member of National Cancer Research Network Testis Cancer ...
-
Dr Ali Amin Al Olama
... has focused on discovery of genetic risk factors of prostate cancer through genome-wide association studies and fine-mapping. I am a core member of an international consortium PRACTICAL (Prostate Cancer Association Group to Investigate Cancer Associated Alterations in the ...
-
Dr Andreas Bender
... large amounts of chemical or biological data related to cancer drug discovery you are very welcome to contact me to see in which way I ...
-
Dr Alejandra Bruna
... aimed to study the effects of the TGF-beta pathway in breast cancer stem cell (BCSC) regulation. To define a role of the TGF-beta pathway in ... of human BCSCs, we have analyzed a panel of breast cancer cell lines that represent the molecular heterogeneity present in primary ...
-
Dr Catherine Lindon
... to coordinated cell division, and have well documented cancer-promoting activities. Ongoing projects in the lab explore how ... in time and space, and how their activity contributes to cancer. We have recently described a 'ubiquitome' of cellular components ...
-
Dr Ashray Gunjur
... broadly interested in immuno-oncology and the link between cancer and the gut microbiome, and am undertaking a PhD supervised by Dr David ... between gut microbiota and outcomes in patients with rare cancer types. ...
-
Dr Ahsan MEMON
... this holographic system was deployed to the study of cancer and stem cell shape regulation and the role of effective membrane ...
-
Dr Aisling Redmond
... She completed postdoctoral fellowships in the breast cancer field at the Royal College of Surgeons in Ireland and Cancer Research UK Cambridge Institute (with Professor Jason Carroll), ...
-
Professor Alan Warren
... how defects in this process cause bone marrow failure and cancer predisposition. Assembly of the two subunits of the ribosome, containing ... it is also important for oncogenesis: a novel class of human cancer predisposition disorder has recently emerged that is caused by mutations ...
-
Dr Fazlur Rahman Talukdar
... alterations linked to esophageal cancer within high-incidence populations worldwide. I am passionate about advancing our ...
-
Dr John Lizhe Zhuang
... lethal cancer often diagnosed at an advanced stage, and its incidence is increasing in Western countries. BO is a relatively common ...
-
Mr Arqum Anwar
... cellular role(s) of a novel factor expected to be involved in DNA damage response. Specifically, the interactome of the protein will be ...
-
Dr Ashwin Seshia
One of the research thrusts in my group is the development of microelectromechanical and microfluidics ...
-
Dr Alvis Brazma
... data analysis. Data integration. Cell cycle. I am in charge of running and developing the transcriptomics data repository ...
-
Dr Annalise Katz-Summercorn
Early detection in oesophageal adenocarcinoma ...
-
Dr Adeeba Fathima Valiya Thodiyil
Single cell/Tissue imaging, quantitative microscopy, image analysis
-
Mrs Barbara Newcombe
1. screening studies (3) for BRCA1&2 mutation tested, male and female 2. SLN technique in early Vulval ...
-
Professor Douglas Easton
... have particular interests in the genetic epidemiology of BRCA1 and BRCA2, intermediate markers of cancer risk (such as breast density), ... in breast (BCAC) and prostate cancer (PRACTICAL), and in BRCA1/2 carriers. ...
-
Mr Harveer Dev
... stability and prostate cancer. Mutations in genes like BRCA1 contribute to the development of various diseases including prostate ...
-
Dr Karoline Kuchenbaecker
... variants that modify breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. Cancer risk prediction. ...
-
Dr Nasim Mavaddat
... risk stratification. I have also worked on risk modelling in BRCA1 and BRCA2 mutation carriers, and more recently, on studying the effect of ...
-
Dr Saif Ahmad
... is focused on understanding a novel mechanism by which the BRCA2 tumour suppressor protein prevents genomic instability, specifically its ...
-
Dr Annalisa Mupo
Acute myeloid leukemia (AML) is a molecularly diverse malignancy representing 15-20% of all childhood and around 35% of all adult leukemias. My work aims to study commonly occurring mutations in AML-NK (normal karyotype) using sophisticated mouse models.
-
Professor Tony Green
Tony Green is Professor of Haemato-oncology in the University of Cambridge and honorary Consultant Haematologist at Addenbrookes Hospital. He was appointed Head of the University Department of Haematology (2000-2020), and in 2016 was appointed Director...
-
Dr Alex Cagan
... superior cancer suppression mechanisms. Studying somatic mutation and clonal dynamics in these species could lead to the discovery of ...
-
Professor Bertie Gottgens
The Göttgens group uses a combination of experimental and computational approaches to study how transcription factor networks control the function of blood stem cells and how mutations that perturb such networks cause leukaemia. This integrated approach...
-
Dr Claudia Ribeiro de Almeida
... and do so by employing hazardous mechanisms of somatic DNA mutation and DNA deletion-recombination with remarkable efficiency. Increasing ... the immunoglobulin heavy-chain (IgH) locus and initiate DNA mutation. At present we are working on understanding how DDX1 and other RNA ...
-
Dr Catherine Green
I run a small group in the Department of Zoology funded by a Cancer Research UK career development fellowship. We are investigating the mechanisms and control of genome replication, both at genetic and epigenetic levels. It is during replication that...
-
Dr Mae Goldgraben
... NGS-based assays for extracted blood DNA to identify variant carriers in familial cases of breast and pancreatic cancer. ...
-
Professor Vincent Gnanapragasam
Vincent J Gnanapragasam holds a personal Chair in Urology at the University of Cambridge and is an Honorary Consultant Urologist at Addenbrooke’s Hospital, Cambridge. He graduated from Newcastle University and following basic surgical training, was...